Schoenberger J A, Glasser S P, Ram C V, McMahon S G, Vanov S K, Leibowitz D A
J Cardiovasc Pharmacol. 1984;6 Suppl 7:S1105-8.
Patients with mild to moderate essential hypertension were treated in four centers with hydrochlorothiazide (HCTZ) 25 mg daily for 4 weeks. Those patients failing to achieve control (supine diastolic blood pressure (DBP) 90 mm Hg or lower) were randomly assigned to nitrendipine (NTP) 5 mg or placebo (PLA) b.i.d. NTP or PLA was increased stepwise to 20 mg b.i.d. as needed to achieve control. Treatment with HCTZ was maintained at 25 mg daily. Eighty-six patients completed the study: 41 in NTP + HCTZ and 45 in PLA + HCTZ groups. Both groups were comparable in baseline characteristics. Supine systolic blood pressure (SBP) was 148.6 +/- 14.4 and DBP was 96.0 +/- 5.4 mm Hg in the NTP + HCTZ group. SBP was 147.4 +/- 16.6 and DBP was 96.4 +/- 5.6 mm Hg in the PLA + HCTZ group. At the end of 7 weeks of titration and treatment with NTP or PLA combined with HCTZ, SBP had fallen to 133.4 +/- 15.1 and DBP to 85.4 +/- 5.9 mm Hg in the NTP + HCTZ group. SBP fell to 138.8 +/- 16.2 and DBP to 90.7 +/- 6.3 mm Hg in the PLA + HCTZ group. The increment in lowering of both SBP and DBP was significantly greater (p = 0.002 and p = 0.0007, respectively) in the NTP + HCTZ group compared to the PLA + HCTZ group.
轻度至中度原发性高血压患者在四个中心接受治疗，每日服用25毫克氢氯噻嗪（HCTZ），持续4周。那些未能实现血压控制（仰卧位舒张压（DBP）90毫米汞柱或更低）的患者被随机分配至每日两次服用5毫克尼群地平（NTP）或安慰剂（PLA）。根据需要，NTP或PLA逐步增加至每日两次20毫克以实现血压控制。HCTZ的治疗维持在每日25毫克。八十六名患者完成了研究：NTP + HCTZ组41例，PLA + HCTZ组45例。两组在基线特征方面具有可比性。NTP + HCTZ组仰卧位收缩压（SBP）为148.6±14.4，DBP为96.0±5.4毫米汞柱。PLA + HCTZ组SBP为147.4±16.6，DBP为96.4±5.6毫米汞柱。在与HCTZ联合使用NTP或PLA进行滴定和治疗7周结束时，NTP + HCTZ组SBP降至133.4±15.1，DBP降至85.4±5.9毫米汞柱。PLA + HCTZ组SBP降至138.8±16.2，DBP降至90.7±6.3毫米汞柱。与PLA + HCTZ组相比，NTP + HCTZ组SBP和DBP降低幅度的增加显著更大（分别为p = 0.002和p = 0.0007）。
